Consideration the changes of renal function for renal cell carcinoma patients, administered the molecular target drugs: axitinib, sunitinib and sorafenib
Not Applicable
Recruiting
- Conditions
- Renal cell carcinoma
- Registration Number
- JPRN-UMIN000019393
- Lead Sponsor
- Dokkyo Medical University, Department of Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Renal cell carcinoma without target lesion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method For renal cell carcinoma patients, we evaluate the blood exam containing a renal function 1,2,4 and 12 weeks later from administration of the molecular target drugs whose daily doses are determined by eGFR (axitinib 10mg, sorafenib 800mg, sunitinib 50mg on over 45), (axitinib 6mg, sorafenib 800mg, sunitinib 37.5mg on low by 45).
- Secondary Outcome Measures
Name Time Method We consider a therapeutic effect by administering the molecular target drug that is axitinib, sunitinib or sorafenib. Therapeutic effect for target lesions is examined using CT. The time for measuring is before and 4, 12weeks later from administration. For the case with preoperative setting, PET is performed before and after administration.